Clinical efficacy of immunotherapy plus targeted therapy in the treatment of postoperative recurrence for hepatocellular carcinoma with bile duct tumor thrombus
10.3760/cma.j.cn115610-20210907-00445
- VernacularTitle:免疫联合靶向治疗原发性肝细胞肝癌合并胆管癌栓术后复发的临床疗效
- Author:
Chuang ZHOU
1
;
Jianwen YE
;
Shengping SONG
;
Wentao LIU
;
Long YU
;
Jianfeng XUE
;
Longshuan ZHAO
;
Wenlong ZHAI
Author Information
1. 郑州大学第一附属医院肝胆胰外科 450052
- Keywords:
Liver neoplasms;
Bile duct tumor thrombus;
Tumor recurrence;
Targeted therapy;
Immunotherapy;
Combination therapy;
Prognosis
- From:
Chinese Journal of Digestive Surgery
2021;20(S2):10-14
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) is rare and enhanced CT or MRI can be used for its diagnosis. Surgical procedure is the main treatment for HCC with BDTT. The authors introduce the experiences of recurrent patient with HCC and BDTT who was treated with targeted therapy plus immunotherapy, in order to provide reference for its clinical diagnosis and treatment.
